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confidence interval 1.38–14.93; p = 0.013). In the LGE-
positive group, an LGE volume greater than the median 
significantly predicted a post-ACh LER of <0 (p = 0.042; 
odds ratio 6.02; 95 % confidence interval 1.07–33.86). 
ACh-provoked coronary vasomotor abnormality is closely 
correlated with myocardial fibrosis in patients with HF but 
without organic coronary stenosis. Coronary vasomotor 
abnormalities in fibrotic myocardium may worsen HF.
Keywords Heart failure · Fibrosis · Magnetic resonance 
imaging · Microvascular dysfunction
Introduction
Myocardial fibrosis is a key component of heart failure (HF). 
There is a substantial body of evidence published over the 
past decade that there is a strong relationship between myo-
cardial fibrosis and worsening of HF [1–5]. The presence 
of late gadolinium enhancement (LGE) in cardiac magnetic 
resonance (CMR) as an indicator of myocardial fibrosis is 
well established [6–8]. The prognostic value of LGE in noni-
schemic-HF has been described in several studies [9–14].
The arterioles are the true intra-myocardial regulatory 
component of the coronary circulation, and these ves-
sels represent the largest proportion (approximately 55 %) 
of the total coronary vascular resistance [15]. Increasing 
of lactate in the coronary circulation is a definitive sign 
of myocardial ischemia, and metabolism of lactate in the 
coronary circulation is possible to compare plasma lactate 
concentration in the aortic root (Ao) and coronary sinus 
(CS) to assess the occurrence of myocardial ischemia dur-
ing coronary angiography [16, 17].
The intracoronary acetylcholine (ACh) provocation 
test is a sensitive, safe test for the assessment of coronary 
Abstract Myocardial fibrosis and microvascular dysfunc-
tion are key determinants of outcome in heart failure (HF); 
we examined their relationship in patients with HF. Our 
study included 61 consecutive patients with HF but with-
out coronary stenosis. All underwent gadolinium-enhanced 
cardiac magnetic resonance to evaluate late gadolinium 
enhancement (LGE) and an acetylcholine (ACh) provoca-
tion test to evaluate microvascular dysfunction. During 
the ACh provocation test, we sampled blood simultane-
ously from the coronary sinus and aortic root to compare 
lactate concentrations. We quantified coronary blood flow 
volume using an intracoronary Doppler-tipped guidewire. 
We detected LGE in 34 patients (LGE-positive); 27 were 
LGE-negative. Coronary blood flow volume increased 
significantly after the ACh provocation test only in LGE-
negative patients (before vs. after ACh, 47.5 ± 36.8 
vs. 69.2 ± 48.0 ml/min, respectively; p = 0.004). The 
myocardial lactate extraction ratio (LER) significantly 
decreased after the ACh test in both groups (LGE-negative, 
p = 0.001; LGE-positive, p < 0.001), significantly more so 
in the LGE-positive group (p = 0.017). Multivariate logis-
tic regression analysis showed that a post-ACh LER < 0 
(indicating myocardial lactate production) was a signifi-
cant predictor of LGE-positivity (odds ratio 4.54; 95 % 
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vasomotor function in the catheterization laboratory. 
Administration of ACh causes vasodilation under normal 
conditions; however, in the presence of endothelial dys-
function it leads to vasoconstriction due to decreasing of 
nitric oxide synthesis [18–21].
Coronary microvascular dysfunction affects the devel-
opment of nonobstructive coronary disease. Microvascular 
dysfunction is also a significant and independent deter-
minant of long-term cardiac events in patients with HF 
[22–31]. However, the correlation between coronary micro-
vascular dysfunction and myocardial fibrosis is not fully 
understood. The aim of this study was to investigate the 
relationship between coronary microvascular circulation 




This study included 61 consecutive patients with suspected 
non-ischemic HF who underwent both cardiac catheteriza-
tion and contrast-enhanced CMR between January 2007 
and December 2013 at Kumamoto University Hospital.
Eligible patients were ≥20 years of age and met the 
criteria for the diagnosis of HF set by the American Col-
lege of Cardiology/American Heart Association Stage 
B or C classification. The patients were clinically stable 
and under optimal medical therapy for HF, including sta-
ble doses of an angiotensin-converting enzyme (ACE) 
inhibitor or angiotensin II receptor blocker (ARB) and a 
β-blocker, if not contraindicated. Twenty-one of the 61 
patients (37.7 %) were, however, unable to tolerate ACE 
inhibitor, ARB or beta blocker therapy because of hypo-
tension even at low doses: seven could not tolerate an ACE 
inhibitor (or ARB) and beta blocker combination therapy, 
and seven could not tolerate either an ACE inhibitor, ARB 
or a beta blocker alone. Thirty-nine of 61 patients (63.9 %) 
had dilated cardiomyopathy (DCM) and eleven of the 
61 patients (18.0 %) had hypertrophic cardiomyopathy 
(HCM) (Table 1).
The following exclusion criteria were applied during 
patient selection: decompensated HF, acute coronary syn-
drome, hypertrophic obstructive cardiomyopathy (HOCM), 
significant coronary stenosis (>50 %), renal insufficiency 
with an estimated glomerular filtration rate of <30 ml/min 
per 1.73 m2, myocarditis, muscular dystrophy, severe car-
diac valvular disease, an implanted cardiac resynchroniza-
tion device, and chronic inflammatory disease.
Written informed consent was obtained from each patient 
before cardiac catheterization. This study was approved by 
the Human Ethics Committee of our institution.
Echocardiograms
Left ventricular ejection fraction (LVEF), left atrial diam-
eter, interventricular septal wall thickness (IVSd) and pos-
terior wall thickness (PWd) were measured by two sonog-
raphers according to the recommendations for chamber 
quantification of the American Society of Echocardiology 
[32].
E/e′ is the ratio between early mitral inflow velocity (E) 
and mitral annular early diastolic velocity (e′); we meas-
ured e′ at the septal mitral annulus. Left ventricular end-
diastolic volume (LVEDV) and left ventricular end-systolic 
volume (LVESV) were calculated by either of the two 
methods described above; LVEF was calculated as follows:
Protocol for CMR
CMR was performed on a 3.0 T magnetic resonance instru-
ment (Achieva 3.0T X-series or Achieva 3.0T X-series TX; 
Philips Medical Systems, Best, The Netherlands). Patients 
were scanned in the supine position using a dedicated 6- 
or 32-channel cardiac torso coil, between January 2007 and 
December 2013.
Double-angulated scout images were obtained to plan 
the cardiac axis views. In all patients, images were acquired 
using T1- and T2-weighted black-blood, electrocardi-
ogram-gated cine imaging by a segmented steady-state 
free-precession sequence in the three long cardiac axes 
with LGE imaging. Approximately 10 min after the injec-
tion of 0.1 mmol/kg of a gadolinium-based contrast agent 
(Magnevist; Bayer Healthcare, Leverkusen, Germany), we 
LVEF = (LVEDV− LVESV) / LVEDV
Table 1  Etiology of HF
Values are presented as n (%)
Other etiologies included cardiac amyloidosis (n = 2), Becker mus-
cular dystrophy (n = 1) and thyrotoxicosis (n = 1)
CM cardiomyopathy
a Defined as a previous history of long-standing hypertension and 
presence of left ventricular hypertrophy (left ventricular mass index 
>101 g/m2 in women and >117 g/m2 in men) with ACC/AHA Stage B 
or C HF, and in the absence of a cause other than hypertension
b Defined as a previous history of uncontrolled diabetes 
(HbA1c > 6.5 %) and left ventricular dysfunction in the absence of a 
cause other than diabetes
n = 61
Dilated CM 39 (63.9)
Hypertrophic CM 11 (18.0)
Hypertensive heart diseasea 5 (8.1)
Diabetic CMb 2 (3.2)
Others 4 (6.5)
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acquired two-dimensional inversion-recovery sequences 
that included the left ventricle from the base to the apex. 
The imaging parameters were: time to repeat/time to 
echo = 4.5/2.2 ms; time of inversion = 250–350 ms; 
acquisition pixel size = 0.95 × 1.13 mm; and slice thick-
ness = 8.0 mm. The acquisition time per slice was approxi-
mately 14 s.
Image analysis
Hyperenhanced myocardial voxels resembling LGE were 
defined as signal intensity higher than 6 standard deviations 
above the mean intensity of the region of interest, which 
was placed over an area of the myocardium evaluated as 
normal [7].
A board-certified cardiovascular radiologist blinded to 
the results of the cardiac catheterization study indepen-
dently determined the dichotomous presence of LGE in the 
left ventricle. The patients were classified into LGE-posi-
tive or LGE-negative groups.
Imaging data were analyzed using commercially avail-
able post-processing software (AZE Virtual Place; AZE, 
Tokyo, Japan). The endocardial and epicardial borders of 
the myocardium were manually traced on each short-axis 
slice. The left ventricular volume was calculated by sub-
tracting the endocardial volume from the epicardial volume 
at end-diastole. Calculations were performed by two car-
diologists blinded to the clinical data. We also calculated 
the  %LGE as the proportion of the LGE volume in the 
total left ventricular volume.
Cardiac catheterization
All vasoactive drugs, including calcium antagonists, 
isosorbide dinitrate, isosorbide mononitrate and nico-
randil were discontinued ≥72 h before the ACh test. We 
performed all examinations the morning after an over-
night fast. A 5 Fr or 6 Fr arterial cannula was placed in 
the radial or femoral artery, and a 6 Fr venous sheath was 
placed in the right femoral vein [27, 28, 33]. A CS catheter 
(Goodtec, Gifu, Japan) was advanced to the CS from the 
venous sheath, and its position was confirmed by contrast-
enhanced fluoroscopy. We performed cardiac catheteriza-
tion and an intracoronary ACh provocation test (100 µg/
min). The lumen diameter of the left anterior descending 
coronary artery (LAD) at end-diastole was measured with 
a computer-assisted coronary angiographic analysis sys-
tem (CAAS 5.6; Pie Medical Imaging B.V., Maastricht, 
The Netherlands) by calibrating the measurement with a 
Judkins catheter as previously reported [34]. The LAD was 
divided into proximal, middle, and distal segments of equal 
length, and each luminal diameter was measured at the 
center of each segment. The coronary artery diameter was 
measured by two blinded investigators at two time points: 
at baseline and 1 min after ACh provocation [18].
Blood was sampled from the CS and the Ao simultane-
ously to measure the plasma lactate concentration [27, 28]. 
The lactate extraction ratio (LER) was calculated by multi-
plying the coronary arteriovenous difference in the lactate 
concentration by 100 and dividing it by the arterial lactate 
concentration as follows [17]:
LER (%) = 100 × (arterial lactate concentration [mg/
dl] − coronary venous lactate concentration [mg/dl])/arte-
rial lactate concentration (mg/dl).
We defined an LER < 0 % as indicative of myocardial 
lactate production.
Additionally, we continuously monitored and evalu-
ated the change of coronary blood supply by measuring the 
quantitative coronary blood flow volume (CBFV) using an 
intracoronary Doppler-tipped guidewire (FloWire; Volcano, 
Rancho Cordova, CA, USA) [27]. The quantitative CBFV 
was calculated as follows [35].
We compared the LER and CBFV before and after the 
ACh provocation test. We then diagnosed microvascu-
lar spasm according to the presence of myocardial lactate 
production and a decrease in the CBFV without epicardial 
vasospasm during the ACh provocation test.
After the ACh test, adenosine triphosphate was admin-
istered into a central vein at 150 µg/kg/min until maximal 
hyperemia was reached as determined by the coronary flow 
reserve (CFR). The CFR was calculated as follows [27]:
CFR = average peak velocity at maximal hyperemia/
average peak velocity at rest.
Assessment by ACh provocation test
All patients were diagnosed by cardiac catheterization as 
previously reported [22, 27]. Epicardial coronary artery 
spasm was angiographically defined as severe vasospasm 
indicated by >90 % lumen narrowing in any of the major 
coronary arteries in response to the ACh test. This defini-
tion is based on the Japanese Circulation Society’s guide-
line for vasospastic angina (epicardial coronary artery 
spasm) [18].
Patients without epicardial coronary artery spasm 
who were positive for lactate production were diagnosed 
with microvascular spasm based on a decrease in the 
CBFV without epicardial vasospasm, but with the occur-
rence of chest symptoms and ischemic changes on an 
electrocardiogram.
Patients who were positive for lactate production 
but had no decrease in the CBFV were diagnosed with 
CBFV = pi × (average peak velocity/2)
× (vessel diameter/2)2
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microvascular dysfunction. Patients who were negative for 
lactate production were further assessed using the CFR. 
Patients with an abnormal CFR were diagnosed with micro-
vascular coronary dysfunction and analyzed along with the 
patients in the microvascular dysfunction group [27].
Patients without abnormal results were considered not to 
have ischemic heart disease (IHD).
Statistical analysis
Normally distributed data are presented as mean ± stand-
ard deviation or median (interquartile range). Differences 
between groups were examined by Student’s t test or the 
Mann–Whitney U test for unpaired data. Categorical val-
ues are presented as number (percentage) and were com-
pared by the Chi-squared test or Fisher’s exact test, as 
appropriate. Variables with a skewed distribution were 
transformed logarithmically before Pearson’s correlation 
to fulfill the conditions required for the type of analysis 
performed.
Univariate logistic regression analysis was performed 
to identify significant parameters related to LGE-positiv-
ity. Multivariate logistic regression analysis was then per-
formed using the forced inclusion model. The Hosmer–
Lemeshow statistic was applied to assess model calibration.
A two-tailed p value of <0.05 was considered statisti-
cally significant. All statistical analyses were performed 
with SPSS, version 20 (IBM Corp., Armonk, NY).
Results
LGE was observed in 34 patients (LGE-positive; 55.7 %) 
(Fig. 1a, b). The median of  %LGE value in the LGE-posi-
tive group was 11.0 % (interquartile range 4.0–18.2 %).
We compared the baseline characteristics of the LGE-
positive (n = 34) and LGE-negative (n = 27) groups. The 
hemoglobin and serum potassium concentrations were sig-
nificantly higher in the LGE-positive group (Table 2). Next, 
we compared the echocardiographic findings between the 
two groups: E/e′ was significantly higher in the LGE-posi-
tive group (Table 3).
Cardiac catheterization revealed that none of the patients 
had >25 % coronary stenosis, and there were coronary vas-
omotor abnormalities in 33 patients (54.0 %; epicardial cor-
onary artery spasm, n = 13; coronary microvascular spasm, 
n = 4; coronary microvascular dysfunction, n = 16). Two 
of the 13 patients who had epicardial coronary artery spasm 
(15.3 %) had trivial atherosclerosis (<25 %). A greater pro-
portion of patients were diagnosed as having non-ischemic 
HF in the LGE-negative group [LGE-negative 17/27 
(62.9 %) vs. LGE-positive 11/34 (32.3 %); p = 0.017] 
(Fig. 1d).
We evaluated the transcardiac LER before and after the 
ACh test. The LER in the ACh test significantly decreased 
in both groups (LGE-negative: before vs. after ACh, 
14.6 ± 17.7 % vs. 1.6 ± 16.6 %, p = 0.001; LGE-positive: 
before vs. after ACh, 15.2 ± 13.3 % vs. −10.0 ± 20.6 %, 
p < 0.001) (Fig. 2a). Additionally, lactate production signif-
icantly increased after ACh provocation only in the LGE-
positive group (p = 0.017) (Table 4). Thus, transcardiac 
lactate production occurred during the ACh test only in the 
LGE-positive group.
The CBFV significantly increased after the ACh provo-
cation test only in the LGE-negative group (before vs. after 
ACh, 47.5 ± 36.8 vs. 69.2 ± 48.0 ml/min; p = 0.004) 
(Fig. 2b). Nonetheless, there was no significant difference 
in CFR between the groups (LGE-negative 2.45 ± 1.46 vs. 
LGE-positive 2.48 ± 1.36; p = 0.93).
Univariate and multivariate logistic regression analyses 
were performed to identify the independent parameters 
associated with LGE on CMR. Late gadolinium enhance-
ment was significantly correlated with an LER < 0 % after 
the ACh provocation test (p = 0.031; odds ratio, 3.37; 95 % 
confidence interval 1.12–10.17) (Table 5).
Finally, in LGE-positive patients, univariate and multi-
variate logistic regression analyses showed that a  %LGE 
of >11.0 % (that is in excess of the median  %LGE) was a 
significant and independent predictor of a post-ACh LER 
of <0 % (p = 0.042; odds ratio, 6.02; 95 % confidence 
interval 1.07–33.86) (Table 6).
Discussion
This is the first study to have investigated the relationship 
between microvascular dysfunction assessed in the ACh 
test and the presence of myocardial fibrosis assessed by 
CMR in patients with nonischemic HF.
Our major findings were: (a) the patient with HF but 
without coronary stenosis had coronary vasomotor dys-
function (Fig. 1d); (b) the LER after the ACh provocation 
test was significantly lower in the LGE-positive group than 
the LGE-negative group (Fig. 2a); (c) myocardial lactate 
production (LER < 0 %) after the ACh test, but not epicar-
dial spasm, was independently and significantly correlated 
with LGE-positivity on CMR (Table 5); and (d) a  %LGE 
value greater than the median independently and signifi-
cantly correlated with myocardial lactate production after 
the ACh test in LGE-positive patients (Table 6).
Wall tension and LGE in HF patients
Lactate production occurred in myocardial tissue with LGE 
on CMR in HF without coronary stenosis, and microvas-
cular dysfunction is therefore a potential cause of cardiac 
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ischemia. In the LGE-positive group, however, lactate pro-
duction increased without a decrease in blood flow during 
the ACh test.
We and others have also previously examined the rela-
tionship between LGE and the transcardiac release of tro-
ponin T, and the relationship between LGE volume with 
LVEDP and transcardiac secretion of B-type natriuretic 
peptide (BNP) in patients with non-ischemic HF [36, 37]. 
Pulmonary capillary wedge pressure (PCWP), LVEDP and 
BNP reflect the extent of cardiac wall tension. Our previ-
ous findings appeared to indicate that myocardial fibrosis 
provokes ongoing myocardial damage, and that the extent 
of myocardial fibrosis is associated with wall tension in 
HF [38]. Furthermore, several groups have reported that 
Fig. 1  Cardiac magnetic 
resonance results and diag-
nostic flow chart with cardiac 
catheterization, a A representa-
tive image of LGE on CMR. b 
In total, 34 of 61 patients who 
underwent CMR exhibited 
LGE (LGE-positive), and the 
other 27 exhibited no LGE 
(LGE-negative). c 22 of the 34 
LGE-positive patients exhib-
ited LGE in the LAD coronary 
artery area, the remaining 12 
patients exhibited LGE in other 
areas. CMR cardiac magnetic 
resonance imaging, LAD left 
anterior descending coronary 
artery, LGE late gadolinium 
enhancement. d Diagnostic flow 
chart for cardiac catheterization. 
All patients were initially pre-
dicted to have nonischemic-HF, 
but 54.0 % of patients showed 
nonobstructive-CAD (epicar-
dial coronary artery spasm, 
coronary microvascular spasm 
and/or coronary microvascular 
dysfunction). CAD coronary 
artery disease
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cardiac wall tension is associated with coronary artery 
spasm [39, 40]. It has been reported that wall tension and 
transcardiac troponin T concentration rise during the ACh 
provocation test [41]. Based on our previous studies and 
the findings of other investigators, transcardiac troponin 
T release would likely increase after the ACh provocation 
test in LGE-positive patients, but we measured only lactate 
concentration in blood sampled simultaneously from the 
Ao and the CS in this study. We speculate that wall ten-
sion induced focal microvascular spasm in LGE-positive 
patients. Drugs that act to lower wall tension by modulat-
ing LVEDP, PCWP and BNP concentration, such as ACE 
inhibitors, ARBs, beta blockers and mineralocorticoid 
blockers, have the potential to ameliorate microvascular 
dysfunction and cardiac fibrosis in HF, and improve patient 
outcomes.
Endothelium‑dependent vasomotor and LGE in HF 
patients
Intra-coronary ACh provocation test is the standard 
method for diagnosing epicardial coronary artery spasm in 
patients without coronary artery stenosis. The ACh test is 
an endothelium-dependent coronary reactivity test used to 
assess endothelial function and coronary artery spasm. We 
previously found that patients with coronary microvascular 
spasm exhibit vascular endothelial dysfunction [22].
In this study, some patients exhibited lactate produc-
tion after the ACh test without a concomitant reduction in 
CBFV. We propose that this may be a consequence of a 
blood flow imbalance that developed due to endothelium-
dependent microvascular dysfunction at the LGE site in 
the coronary artery during the test. Indeed, 64.7 % of the 
patients in the LGE-positive group exhibited LGE in the 
LAD area (Fig. 1c). Moreover, logistic regression analyses 
showed a strong relationship between  %LGE and lactate 
production in the ACh test (Tables 5, 6).
Based on these study results, we speculate that myo-
cardial fibrosis could indicate the presence of cardiac 
ischemia, which in turn induces further myocardial fibrosis. 
Therefore, a vicious circle involving cardiac fibrosis and 
ischemia may be occurring in HF.
It has been reported that patients with HF have more 
extensive coronary microvascular rarefaction and myocar-
dial fibrosis than normal patients, and that the progression 
of coronary microvascular rarefaction correlates with myo-
cardial fibrosis [42]. Therefore, coronary rarefaction may 
have been occurring in parallel with microvascular dys-
function in LGE-positive patients in this study. In addition, 
it is reported that pharmacologic treatment with an ACE 
inhibitors, ARBs and MR blockers reduce cardiac fibrosis 
and repair microvascular dysfunction in non-ischemic HF 
[43–46]. Based on these reports, it is essential to achieve 
optimal medical therapy with an ACE inhibitor (or ARB) 
and a beta blocker, especially for patients with HF and 
myocardial fibrosis.
Study limitations
This study had some limitations. First, the etiology of HF 
in the cohort was heterogeneous, and the mechanisms of 
lactate production may have differed among cardiomyopa-
thies. In particular, DCM or other cardiomyopathy differ 
pathophysiological mechanisms far from HCM. In addition, 
HCM rarely occur HF and are used different medication 
Table 2  Patient characteristics
Values are presented as mean ± standard deviation, median (inter-
quartile range) or n (%)
No significant differences were present in the baseline characteristics 
or medications between the two groups. With respect to the labora-
tory data, the hemoglobin and serum potassium concentrations were 
higher in the LGE-positive group than the LGE-negative group
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II 
receptor blocker, BNP brain natriuretic peptide, hs-TnT high-sensitiv-
ity serum troponin T, LGE late gadolinium enhancement, MR miner-
alocorticoid receptor
Variable LGE(−), n = 27 LGE(+), n = 34 p value
Age in years 58.6 ± 14.3 59.1 ± 16.5 0.90
Sex, male 18 (66.7) 25 (73.5) 0.56
Body mass index in 
kg/m2
23.8 ± 4.5 24.4 ± 3.9 0.61
Hypertension 17 (62.9) 20 (58.8) 0.83
Diabetes 9 (33.3) 6 (17.6) 0.17
Atrial fibrillation 11 (40.7) 7 (20.6) 0.089
Smoking history 17 (62.9) 20 (58.8) 0.89
Medications
 ACE-I/ARB 21 (77.8) 26 (76.4) 0.90
 β-blocker 18 (66.7) 29 (85.3) 0.10
 Loop diuretic 9 (33.3) 11 (32.3) 0.93
 MR antagonist 7 (25.9) 14 (41.1) 0.21
 Calcium antagonist 5 (18.5) 10 (29.4) 0.32
Laboratory data
 White blood cells 
(per µl)
5644 ± 2950 6111 ± 1155 0.09
 Hemoglobin (in g/dl) 13.3 ± 2.1 14.8 ± 1.9 0.005
 Serum albumin  
(in mg/dl)
3.94 ± 0.55 4.14 ± 0.42 0.11
 Serum sodium  
(in mEq/L)
139.6 ± 2.6 139.8 ± 1.8 0.74
 Serum potassium  
(in mEq/L)
4.24 ± 0.41 4.47 ± 0.41 0.03
 Serum creatinine  
(in mg/dl)
0.78 ± 0.16 0.89 ± 0.23 0.052
 ln(hs-TnT) 0.90 (0.25–1.56) 1.36 (0.93–1.80) 0.12
 ln(BNP) 5.45 (4.17–6.72) 5.40 (4.84–5.96) 0.40
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from other cardiomyopathy. To establish the extent of 
this possible limitation, we excluded HCM patients from 
this study and examined the relationship between LGE 
and microvascular dysfunction using the same methods. 
In the patients without HCM (n = 50) in this study, The 
CBFV significantly increased after the ACh provoca-
tion test in the LGE-negative group (before vs. after ACh, 
47.8 ± 38.1 vs. 72.1 ± 48.7 ml/min; p = 0.003, n = 26), 
but the CBFV did not increased after the ACh provoca-
tion test in the LGE-positive group (before vs. after ACh, 
57.7 ± 35.0 vs. 67.5 ± 44.0 ml/min; p = 0.30, n = 24). 
The LER in the ACh test significantly decreased in both 
groups (LGE-negative: before vs. after ACh, 13.7 ± 18.0 
vs. 1.2 ± 16.6 %, p = 0.013; LGE-positive: before vs. after 
ACh, 16.5 ± 14.9 % vs. −11.2 ± 21.6 %, p < 0.001), and 
lactate production significantly increased after ACh provo-
cation only in the LGE-positive group (p = 0.021). LGE 
was significantly and independently correlated with an 
LER < 0 % after the ACh provocation test in the multi-
variate logistic regression analyses (p = 0.009; odds ratio, 
13.47; 95 % confidence interval 1.90–95.24). These results 
in the patients without HCM (n = 50) were almost same as 
the results of all study patient (n = 61) (Fig. 2a, b; Table 5). 
Our results of HF patients with (n = 61) or without HCM 
(n = 50) indicated that LGE on CMR correlated with lac-
tate production after the ACh provocation test and coronary 
microvasomotor abnormality.
Second, we enrolled a relatively small number of 
patients from a single center, limited to patients with HF 
but without coronary stenosis. Many patients declined to 
undergo cardiac catheterization, as they had no chest pain; 
Table 3  Echocardiography results
Values are presented as mean ± standard deviation
E/e′ was significantly higher in the LGE-positive group than the 
LGE-negative group
DcT deceleration time of mitral inflow, E/A ratio of early transmitral 
velocity (E) to late transmitral velocity (A), E/e′ ratio of early trans-
mitral velocity (E) to tissue Doppler early diastolic velocity (e′), IVSd 
interventricular septum thickness (diastolic), LVDd left ventricular 
dimension (diastolic), LVEF left ventricular ejection fraction, PWd 
left ventricular posterior wall thickness (diastolic)
Parameter LGE(−), n = 27 LGE(+), n = 34 p value
LVDd in mm 53.7 ± 6.5 51.9 ± 9.9 0.440
LVEF in % 43.6 ± 13.1 44.8 ± 12.9 0.716
IVSd in mm 10.8 ± 2.8 11.9 ± 3.3 0.158
PWd in mm 10.3 ± 2.9 11.1 ± 2.4 0.246
E/A 1.04 ± 0.54 1.23 ± 0.60 0.235
DcT in ms 182.2 ± 42.7 205.3 ± 86.3 0.208
E/e′ 11.2 ± 3.7 13.4 ± 4.0 0.035
Fig. 2  Results of cardiac catheterization. a Comparison of the LER 
in HF with or without LGE. The LER decreased significantly in the 
LGE-positive during the ACh provocation test. LER of <0 % indi-
cates lactate production by the myocardium. ACh acetylcholine, LER 
lactate extraction ratio, LGE late gadolinium enhancement. b Com-
parison of the coronary blood flow volume in HF with or without 
LGE. The coronary blood flow volume increased significantly only in 
the LGE-negative group during the ACh provocation test
Table 4  Results of ACh provocation test
Values are presented as n (%)
ECG change, chest pain and epicardial spasm had no difference 
between two groups
Lactate Production equates to a lactate extraction ratio <0 %
ACh acetylcholine, ECG electrocardiogram, LGE late gadolinium 
enhancement
LGE(−) n = 27 LGE(+) n = 34 p value
ECG change 10 (37.0) 13 (38.2) 0.92
Chest pain 4 (14.8) 8 (23.5) 0.40
Lactate production 10 (37.0) 23 (67.6) 0.017
Epicardial spasm 3 (11.1) 10 (29.4) 0.27
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consequently we were only able to recruit 61 patients in 
7 years. Indeed, 35 patients rejected invasive cardiac cath-
eterization because they were diagnosed as having non-
ischemic heart disease before hospitalization.
Third, 21 patients (34.4 %) could not tolerate ACE 
inhibitor, ARB or beta blocker therapy even at low doses 
because of hypotension. It has been reported that ACE 
inhibitors, ARBs and beta blockers influence microvascular 
function [47]; however, both would be expected to have 
less of an impact on microvascular function than calcium 
channel blockers or nitrates.
Fourth, we examined coronary microvascular function in 
the LAD alone, as in our opinion it would have been too time-
consuming and invasive to perform an ACh provocation test 
in both coronary arteries. Indeed, 22 of the 34 LGE-positive 
patients (64.7 %) exhibited LGE in the LAD area (Fig. 1c).
Table 5  Univariate and 
multivariate logistic regression 
analysis of lge-positive findings 
in all study patients (n = 61)
Lactate production from myocardium (LER < 0) after the ACh test was independently and significantly 
correlated with LGE positivity
ACh acetylcholine, CI confidence interval, LER lactate extraction ratio, LGE late gadolinium enhancement, 
OR odds ratio, PCWP pulmonary capillary wedged pressure
Varieties Univariate analysis Multivariate analysis
p value OR (95 % CI) p value OR (95 % CI)
Age (per year) 0.56 1.39 (0.46–4.19)
Male (yes) 0.90 1.00 (0.97–1.04)
Body mass index (per kg/m2) 0.38 1.07 (0.92–1.24)
Hypertension (yes) 0.49 1.57 (0.44–5.64)
Dilated cardiomyopathy (yes) 0.049 0.32 (0.10–1.00) 0.051 0.31 (0.09–1.17)
Atrial fibrillation (yes) 0.09 0.38 (0.12–1.17) 0.23 0.45 (0.13–1.63)
LVEF at echocardiogram (per %) 0.71 1.01 (0.97–1.05)
E/e′ at echocardiogram >12 (yes) 0.55 1.36 (0.49–3.81)
Cardiac index (per ml/min) 0.62 1.26 (0.51–3.11)
PCWP (per mmHg) 0.51 1.05 (0.91–1.21)
LER after ACh test ≤0 (yes) 0.019 3.56 (1.23–10.27) 0.031 3.37 (1.12–10.17)
Epicardial spasm (yes) 0.16 2.50 (0.68–9.13) 0.69 1.36 (0.29–6.39)
Table 6  Univariate and 
multivariate logistic regression 
analyses of an LER of <0 % 
after the ACh-provocation 
test in LGE-positive patients 
(n = 34)
%LGE was independently and significantly correlated with an LER < 0 % after the ACh-provocation test in 
LGE-positive patients (n = 34)
%LGE is expressed as the percentage of LGE volume to total left ventricular volume
ACh acetylcholine, CI confidence interval, LER lactate extraction ratio, LGE late gadolinium enhancement, 
OR odds ratio, PCWP pulmonary capillary wedged pressure
* >11.0 % (=median of %LGE)
Varieties Univariate analysis Multivariate analysis
p value OR (95 % CI) p value OR (95 % CI)
Age (per year) 0.30 0.98 (0.93–1.02)
Male (yes) 0.45 0.51 (0.09–2.99)
Body mass index (per kg/m2) 0.11 1.21 (0.96–1.52) 0.14 1.22 (0.94–1.59)
Hypertension (yes) 0.73 1.30 (0.30–5.54)
Dilated cardiomyopathy (yes) 0.55 1.56 (0.37–6.62)
Atrial fibrillation (yes) 0.51 0.56 (0.10–3.10)
LVEF at echocardiogram (per %) 0.58 1.02 (0.96–1.08)
E/e′ at echocardiogram > 12 (yes) 0.71 0.76 (0.18–3.23)
Cardiac index (per ml/min) 0.55 0.67 (0.17–2.55)
PCWP (per mmHg) 0.28 1.13 (0.91–1.39)
%LGE ≥ median* (yes) 0.046 5.00 (1.03–24.28) 0.042 6.02 (1.07–33.86)
Epicardial spasm (yes) 0.007 18.47 (2.22–153.44) 0.06 9.26 (0.88–97.83)
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Fifth, the quantitative analysis of myocardial fibrosis by 
LGE is that the fibrotic process is often diffuse in nonis-
chemic cardiomyopathies, and the extent of LGE may be 
underestimated in such patients because of the lack of nor-
mal, non-fibrotic myocardium as a reference.
Finally, we used LGE to evaluate myocardial fibrosis 
rather than extracellular volume fraction (ECV). Although 
ECV is now an extensively validated method of measur-
ing myocardial fibrosis, this was not the case at the start of 
our study [48–54]. To minimize the influence of the limita-
tions of measuring LGE, we undertook CMR only when 
the patients’ symptoms and hemodynamic statuses were 
stable.
Conclusion
Late gadolinium enhancement on cardiac magnetic reso-
nance is correlated with lactate production in the acetyl-
choline provocation test. The presence of late gadolinium 
enhancement indicates ischemic damage due to coronary 
vasomotor abnormality. Late gadolinium enhancement in 
patients with HF may indicate worsening of HF. Further 
research is required to understand the role of myocardial 
fibrosis in HF more fully, and to identify new means of fur-
ther improving patient outcomes.
Translational Outlook: Patients with nonischemic HF 
exhibiting LGE on CMR likely have ischemia caused by 
vasomotor abnormality.
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